M&A / Deals UK’s Claret Capital raises 575m for European biotechs PharmaphorumLondon-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising 575m for "Europe's boldest innovators."Read full story pharminent September 7, 2026 (Last updated: September 7, 2026) Pharmaphorum London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising 575m for “Europe’s boldest innovators.” Read full story Post navigation Previous: Novartis hit as Lp(a) drug fails cardio outcomes trialNext: Novartis and Ionis’ Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026